Typical Timeframe for Factor V Leiden Mutation Laboratory Results

Laboratory Testing Methods and Processing

Factor V Leiden mutation can be detected through either direct DNA-based genotyping or a Factor V Leiden-specific functional assay 1
Most laboratories use PCR-based DNA testing methods which offer high analytical validity with error rates of only about 1.0% 2, 3
Sample collection requires whole blood at room temperature for DNA testing, which is simpler than the special handling required for functional assays that need citrated frozen plasma 1, 4
Laboratory proficiency testing data shows high reliability with overall correct response rates between 98.9% and 99.6% 2, 5

Local vs. reference laboratory testing: In-house testing may be completed more quickly than samples sent to reference laboratories 2
Sample processing requirements: DNA extraction must be completed before genetic analysis can begin 3
Laboratory workload: High volume periods may extend turnaround times 2

Proficiency testing programs regularly assess laboratory performance through interlaboratory comparisons 2, 3
The College of American Pathologists (CAP) survey data shows consistently high accuracy rates for Factor V Leiden testing 2

While waiting for results, clinicians should consider interim management based on clinical presentation and risk factors 3, 6
For patients with suspected thrombophilia, other coagulation tests may be performed simultaneously to assess for additional risk factors 7
The high analytical validity of Factor V Leiden testing (sensitivity 98.8%, specificity 99.3%) means results are generally reliable when they do arrive 2, 3

Requesting "stat" testing is generally not helpful as the genetic testing process requires specific steps that cannot be significantly expedited 3
Initiating anticoagulation therapy should not be delayed while waiting for Factor V Leiden results if clinically indicated 6
Interpreting results requires consideration of clinical context, as the presence of Factor V Leiden increases thrombosis risk but does not guarantee thrombotic events will occur 6, 8

The American College of Medical Genetics recommends DNA-based testing for patients on anticoagulants like Eliquis, as it is not affected by the medication 9, 10
DNA-based genotyping is a reliable method for detecting the R506Q mutation in the Factor V gene, with correct response rates between 98.9% and 99.6% 9, 10
Functional APC resistance assays may be affected by anticoagulants like Eliquis and are not recommended for patients on these medications 9, 11, 12
For patients on Eliquis or other anticoagulants, direct DNA testing is the recommended approach rather than functional assays 9, 10
The American College of Medical Genetics specifically states that patients on anticoagulant therapy should proceed directly to molecular testing, which applies to patients on direct oral anticoagulants like Eliquis 9, 11

DNA testing offers the advantage of distinguishing between heterozygotes and homozygotes, which has important clinical implications since homozygotes have approximately 10-fold higher risk of thrombotic events 9
Homoziygotes for Factor V Leiden have a significantly higher risk of thrombotic events compared to heterozygotes, making DNA testing crucial for risk assessment 9

The American Society of Hematology recommends that Factor V Leiden is a thrombophilic disorder that does not affect the intrinsic coagulation pathway measured by aPTT, and routine aPTT testing will not detect this mutation 13, 14

Factor V Leiden involves a specific point mutation (R506Q) in the Factor V gene that makes Factor V resistant to inactivation by activated protein C, but does not affect the quantity or baseline function of Factor V in standard coagulation assays 13, 14
Standard aPTT testing cannot distinguish between normal Factor V and the mutant Factor V Leiden variant because both function normally in the absence of activated protein C 13, 14

The International Society on Thrombosis and Haemostasis recommends that the correct test for Factor V Leiden is either DNA-based genotyping or an activated protein C resistance (APC-R) assay, not aPTT 13, 14

APTT-based APC-R assays with predilution in Factor V-deficient plasma have near 100% sensitivity and specificity for Factor V Leiden mutations 13, 14
These assays measure the prolongation of aPTT in response to added activated protein C—Factor V Leiden shows reduced prolongation (resistance) 13, 14

Do not delay thrombophilia workup because aPTT is normal—this is expected in Factor V Leiden 13, 14
Do not order aPTT to screen for Factor V Leiden—it will not detect the mutation and may provide false reassurance 13
Avoid functional APC-R assays in patients on direct oral anticoagulants (DOACs)—these can falsely elevate APC-R ratios and miss the diagnosis; use DNA testing instead 13, 14